393Vancomycin Dosing in Obese Patients

نویسندگان

  • Mohammed Alquwaizani
  • David W. Kubiak
  • David Sansonetti
  • Megan Barra
  • Michael S. Calderwood
چکیده

Background. Current guidelines for systemic vancomycin dosing recommended using actual body weight (ABW) regardless of body mass index (BMI). We sought to evaluate the effect of this dosing strategy in obese patients with BMI ≥35. Methods. Retrospective cohort study of patients ≥18 years old with a BMI ≥35 hospitalized between January 1, 2011 and December 31, 2013 with at least 3 doses of intravenous vancomycin. Inclusion required a normal baseline creatinine clearance (CrCl ≥45 mL/minute) and at least 1 appropriate vancomycin trough measured before the 4or later dose. Patients were excluded if they received a loading dose or if the maintenance dose was changed before the first trough was measured. We collected data on patient’s age, gender, weight (actual, ideal, and dosing), baseline creatinine, calculated CrCl, administered vancomycin dose (including frequency and total daily dose), and vancomycin trough. Linear regression was used to predict the vancomycin trough based on each of these clinical predictors. Results. The 68 patients identified had a significant positive linear relationship between vancomycin total daily dose (TDD) (mg/kg/day) based on ideal body weight (IBW) and vancomycin trough (p 0.001). The relationship was not significant for vancomycin TDD based on ABW (p 0.072). Other predictors of vancomycin trough included age, gender, and baseline serum creatinine. Multivariable modeling including these predictors, along with vancomycin TDD based on IBW, showed moderate correlation between predicted and actual vancomycin troughs (R>0.41). For the average patient in our study, initial doses of 30 mg/kg/day (IBW) predicted vancomycin troughs of 10-15 mcg/mL. To achieve targets of 15-20 mcg/mL, our model suggested that initial doses of 45-60 mg/kg/day (IBW) should be used. Younger patients and male patients were less likely to achieve therapeutic targets without this higher dosing. Conclusion. For patients with a BMI ≥35, vancomycin dosing based on IBW rather than ABWappears to be more predictive of vancomycin trough, with initial doses of at least 45 mg/kg/day (IBW) more likely to achieve higher vancomycin trough targets. Given the only moderate correlation, it remains important to follow vancomycin troughs and adjust dosing accordingly. Disclosures. All authors: No reported disclosures.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population

Aminoglycoside dosing has been studied in the obese population, typically recommending an adjusted weight utilizing a 40% dosing weight correction factor (IBW + 0.4 × (TBW-IBW)). These studies included limited numbers of morbidly obese patients and were not done in the era of extended interval aminoglycoside dosing. Here, we report a retrospective evaluation of morbidly obese patients receiving...

متن کامل

Antibiotic therapy of pneumonia in the obese patient: dosing and delivery

PURPOSE OF REVIEW Obesity has been shown to be associated with antibiotic underdosing and treatment failure. This article reviews the recent literature on antibiotic dosing in obese patients with pneumonia. RECENT FINDINGS Obesity is associated with several alterations in antibiotic pharmacokinetics and pharmacodynamics, including increases in the antibiotic volume of distribution and clearan...

متن کامل

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.

WHAT IS KNOWN AND OBJECTIVE Obesity is a significant burden on the healthcare system in the United States, and determining the appropriate antimicrobial dosing regimen in morbidly obese patients is challenging. Morbidly obese patients have documented differences in pharmacokinetic and pharmacodynamic properties compared to normal-weight patients, which impact antibiotic efficacy and toxicity. T...

متن کامل

Retrospective Evaluation of Dosing Body Weight for Unfractionated Heparin in Obese Patients

Purpose: Using adjusted body weight (AdjBW) for heparin dosing in obese patients is a common but not validated clinical practice. The purpose of this study was to evaluate whether using AdjBW in obese patients would lead to quick achievement of therapeutic activated partial thromboplastin time (aPTT) and low bleeding risk with heparin therapy. Methods: A retrospective cohort study was conducted...

متن کامل

Evaluation of an Unfractionated Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients.

BACKGROUND Despite large interpatient variability in dose response, heparin is utilized for treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in obese patients are conflicting. OBJECTIVE The objective was to evaluate the time and dose required to achieve a therapeutic activated partial thromboplastin time (aPTT) in nonobese, obese, and severely obese patien...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 1  شماره 

صفحات  -

تاریخ انتشار 2014